Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; ...

Baseline factors linked to SLE flares during pregnancy included thrombocytopenia and a history of LN, while antimalarial therapy demonstrated protective effects.

Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, ...

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

CKD and ESRD can have unpleasant cutaneous manifestations, including alopecia, but there are several helpful approaches to mitigating hair loss.

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Patients receiving ICIs were associated with a greater risk of developing RA, but lower risks for SLE and SSc.

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory ...

HRT may be safe for people with lupus in certain instances. One 2022 review involving 16 studies found that HRT can help ...

A new study finds that ChatGPT4 provides answers to lupus patient questions as effectively as rheumatologists, excelling in ...